Celltrion Goes It Alone With First Solo US Biosimilar Launch
Vegzelma Is The Fourth FDA-Approved Bevacizumab Rival To Avastin
Celltrion is taking a major step forward in the US with its first direct launch of a biosimilar through its own front-end operation. The Korean firm’s Vegzelma rival to Avastin will be looking to compete with multiple other versions of bevacizumab already in the market.
You may also be interested in...
Celltrion Bags FDA Approval For High-Concentration Humira Rival
Celltrion has won US FDA approval for its Yuflyma 100mg/ml adalimumab biosimilar, making it the third high-concentration version approved in the US and the ninth Humira rival overall.
Celltrion CCO On The Big US Build-Up, Direct Sales Model
Celltrion USA’s chief commercial officer Thomas Nusbickel tells Scrip how he’s shaping the South Korean group’s operations ahead of key launches that include assets in the immunology segment. He also weighs in on whether big pharma will stay in the biosimilars game over the long term.
Who's Hired? Padagis Gets New Leadership
Former Perrigo Rx business Padagis has seen a leadership change, while Celltrion has appointed a new chief commercial officer for the US. Meanwhile, Biosimilars Canada has elected a new chair and Australia’s GBMA has welcomed fresh board members.